Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58 Small Cell Lung Carcinoma 22 Carcinoma, Hepatocellular 17 Neoplasms 15 Lung Neoplasms 14 Biliary Tract Neoplasms 12 Neoplasm Metastasis 11 Breast Neoplasms 11 Recurrence 10 Squamous Cell Carcinoma of Head and Neck 9 Melanoma 9 Carcinoma 9 Advanced Solid Tumors 8 Triple Negative Breast Neoplasms 7 Stomach Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 7 Liver Neoplasms 7 Head and Neck Neoplasms 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Carcinoma, Renal Cell 6 Prostatic Neoplasms 5 Lymphoma 5 Uterine Cervical Neoplasms 4 Neoplasms by Site 4 Multiple Myeloma 4 Lymphoma, Follicular 4 Colorectal Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Cancer × durvalumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡